SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTheracryf PLC Regulatory News (TCF)

Share Price Information for Theracryf PLC (TCF)

Share Price is delayed by 15 minutes
Get Live Data
0.24    0.00 (0.00%)
Bid:
0.23
Ask:
0.25
Spread: 0.02 (8.696%)
Market Cap: £5.16m
TCF Live PriceLast checked at - London Stock Exchange

Intraday Theracryf PLC Share Chart

Holding(s) in Company

16 May 2025 13:00

RNS Number : 0614J
Theracryf PLC
16 May 2025
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BSVYN304

Issuer Name

THERACRYF PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of financial instruments

3. Details of person subject to the notification obligation

Name

Spreadex LTD

City of registered office (if applicable)

St. Albans

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

14-May-2025

6. Date on which Issuer notified

15-May-2025

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

3.723200

0.606800

4.330000

93050001

Position of previous notification (if applicable)

3.757000

0.142800

3.899800

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BSVYN304

80009545

3.723200

Sub Total 8.A

80009545

3.723200%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

CFD/Spread Bet

13040456

0.606800

Sub Total 8.B1

13040456

0.606800%

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

Sam Meisel01727 895138Spreadex is an FCA regulated provider of spread betting and CFD trading. Founded in 1999, Spreadex gives both retail and professional traders the opportunity to trade over 10,000 global markets, including UK small caps. For more information see www.spreadex.com/financials.

12. Date of Completion

16-May-2025

13. Place Of Completion

UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFELEAIRLIE
12
Date   Source Headline
26th May 20262:40 pmRNSHolding(s) in Company
15th May 202612:43 pmRNSHolding(s) in Company
15th May 20267:00 amRNSHolding(s) in Company
14th May 20267:00 amRNSPositive Ox-1 tox data in addiction programme
21st Apr 20267:00 amRNS-RInvestor Webinar
20th Apr 20267:00 amRNSSuccessful GMP Manufacture Advances Ox-1 to Clinic
16th Apr 20267:00 amRNSNew Manufacturing Process Patent for Ox-1
14th Apr 20267:00 amRNSNon-Binding Proposal to Acquire TheraCryf’s Assets
23rd Mar 20267:00 amRNSOx-1 Programme Advances to Final Toxicology Study
26th Jan 20267:00 amRNSOx-1 Addiction Programme Update
5th Jan 20267:00 amRNSKey Ox-1 milestone & notice of investor webinar
18th Dec 20257:00 amRNS-RPotential of Preclinical Program in Mental Fatigue
3rd Dec 20257:00 amRNSHalf-year Financial Report
26th Nov 20257:00 amRNS-RMarking Addiction Awareness Week
24th Nov 20257:00 amRNSNotice of Results
3rd Nov 20257:00 amRNSOx-1 Programme Achieves Manufacturing Milestone
16th Oct 20254:45 pmRNSHolding(s) in Company
16th Oct 20254:45 pmRNSDirector/PDMR Shareholding
10th Oct 20257:00 amRNS-RWorld Mental Health Day & Q4 Conference Schedule
26th Sep 20253:45 pmRNSHolding(s) in Company
8th Sep 202511:38 amRNSHolding(s) in Company
4th Sep 20257:00 amRNSOx-1 Patent Grant & Development Programme Update
4th Aug 20253:27 pmRNSHolding(s) in Company
17th Jul 20257:00 amRNSManufacturing Scale Up of Lead Ox-1 Programme
9th Jul 20253:07 pmRNSResult of AGM
9th Jul 20257:00 amRNSAGM Statement
16th Jun 20254:10 pmRNSNotice of AGM
13th Jun 20257:00 amRNSChange of Adviser
10th Jun 202512:32 pmRNS-ROx-1 Investor Presentation
3rd Jun 20257:00 amRNSFinal results for year to 31 March 2025
23rd May 20257:14 amRNSNotice of Results and Ox-1 presentation
22nd May 202512:43 pmRNSHolding(s) in Company
22nd May 202512:22 pmRNSDirector/PDMR Shareholding
16th May 20251:00 pmRNSHolding(s) in Company
12th May 20257:00 amRNSMaster Service Agreement signed for Ox-1 programme
1st May 20257:00 amRNSBoard Appointment, Grant of Options, PDMR Dealing
26th Mar 20257:00 amRNS-RInvestor webinar
21st Mar 20253:55 pmRNSHolding(s) in Company
20th Mar 20253:33 pmRNSHolding(s) in Company
20th Mar 202511:01 amRNSHolding(s) in Company
19th Mar 202512:10 pmRNSHolding(s) in Company
17th Mar 20252:17 pmRNSHolding(s) in Company
17th Mar 20257:00 amRNSHolding(s) in Company
17th Mar 20257:00 amRNSHolding(s) in Company
17th Mar 20257:00 amRNSHolding(s) in Company
13th Mar 20257:00 amRNSHolding(s) in Company
12th Mar 20252:03 pmRNSHolding(s) in Company
12th Mar 20251:59 pmRNSHolding(s) in Company
11th Mar 202510:17 amRNSHolding(s) in Company
7th Mar 202512:04 pmRNSResult of General Meeting
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.